NevroNVRO
About: Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
Employees: 1,099
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
18% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 39
7% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 28
2% less funds holding
Funds holding: 130 [Q3] → 128 (-2) [Q4]
5.54% less ownership
Funds ownership: 101.56% [Q3] → 96.02% (-5.54%) [Q4]
37% less capital invested
Capital invested by funds: $212M [Q3] → $134M (-$77.8M) [Q4]
50% less call options, than puts
Call options by funds: $2.32M | Put options by funds: $4.61M
100% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 0 (-2) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Canaccord Genuity William Plovanic 46% 1-year accuracy 22 / 48 met price target | 0%upside $5.85 | Hold Maintained | 7 Feb 2025 |
Piper Sandler Adam Maeder 57% 1-year accuracy 8 / 14 met price target | 0%upside $5.85 | Neutral Upgraded | 7 Feb 2025 |
Financial journalist opinion
Based on 5 articles about NVRO published over the past 30 days
